real-time benefit information as part of such sponsor’s electronic prescription program under the Medicare program. Sec. 118. Requiring prescription drug plans and MA–PD plans to report potential fraud, waste, and abuse to the Secretary of HHS. Sec. 119. Establishment of pharmacy quality measures under Medicare part D. TITLE II—Drug Price Transparency Sec. 201. Reporting on explanation for drug price increases. Sec. 202. Public disclosure of drug discounts. Sec. 203. Requiring certain manufacturers to report drug pricing information with respect to drugs under the Medicare program. Sec. 204. Making prescription drug marketing sample information reported by manufacturers available to certain individuals and entities. Sec. 205. Providing the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information. Sec. 206. Sense of the Senate regarding the need to expand commercially available drug pricing comparison platforms. TITLE III—Revenue Provisions Sec. 301. Permanent extension of reduction in medical expense deduction floor. Sec. 302. Safe harbor for high deductible health plans without deductible for insulin. Sec. 303. Inclusion of certain over-the-counter medical products as qualified medical expenses. TITLE IV—Miscellaneous Sec. 401. Improving coordination between the Food and Drug Administration and the Centers for Medicare & Medicaid Services. Sec. 402. Patient consultation in Medicare national and local coverage determinations in order to mitigate barriers to inclusion of such perspectives. Sec. 403. MedPAC report on shifting coverage of certain Medicare part B drugs to Medicare part D. Sec. 404. Requirement that direct-to-consumer advertisements for prescription drugs and biological products include truthful and non-misleading pricing information. Sec. 405. Chief Pharmaceutical Negotiator at the Office of the United States Trade Representative. I Medicare Parts B and D A Medicare Part B Provisions